Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

RARE PHOTOS: What to expect from regeneron s next quarterly earnings report | Vintage Vibes

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara.

The company is expected to report its Q1 earnings on Tuesday, Apr. 29, before the market opens. Ahead of the event, analysts expect REGN to report an EPS of $7 per share, down 12.2% from $7.97 per share reported in the year-ago quarter. It has exceeded analysts' earnings estimates in three of the past four quarters, while only missing in one occassion. Its EPS of $9.90 in the recent quarter surpassed analysts’ expectations by 2.9%, driven by higher sales of its Dupixent, EYLEA HD and EYLEA, and Libtayo. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.